Medicenna Therapeutics (TSE:MDNA) Hits New 52-Week Low - Time to Sell?

Key Points

• 52-week low: Shares fell to C$0.67 (down ~5.7%) on Monday with about 113,007 shares traded, after closing at C$0.70.
• Weak financials: Market cap is C$55.06M; the company reported Q4 EPS of C($0.05), has a negative ROE and extremely negative net margin, and analysts forecast -0.37 EPS for the year.
• Business focus: Medicenna is a Canada-based immuno-oncology developer of "Empowered Cytokines" targeting the IL-4 receptor across multiple cancers, with 50- and 200-day moving averages of C$0.86 and C$1.06 indicating a downtrend.

Shares of Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report) reached a new 52-week low during trading on Monday . The company traded as low as C$0.67 and last traded at C$0.67, with a volume of 113007 shares. The stock had previously closed at C$0.70.

Medicenna Therapeutics Stock Down 5.7%

The company has a market capitalization of C$55.06 million, a P/E ratio of -4.40 and a beta of 2.51. The company has a debt-to-equity ratio of 3.30, a quick ratio of 4.65 and a current ratio of 2.68. The firm's fifty day moving average is C$0.86 and its 200-day moving average is C$1.06.

Medicenna Therapeutics (TSE:MDNA - Get Free Report) last released its quarterly earnings results on Friday, February 13th. The company reported C($0.05) earnings per share for the quarter. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%. As a group, equities research analysts predict that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.